# Universal DX

Source: https://onco.cc/companies/universal-dx/  
OnCo record `universal-dx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Universal DX is developing Signal-C, a blood test to screen for bowel cancer and pre-cancerous growths, and has partnered with Quest Diagnostics to offer it in the US once regulators approve it.

## Summary

Universal DX (UDX), incorporated in Spain in 2012 and headquartered in Madrid, develops cell-free DNA blood tests for early cancer detection. Its lead assay, Signal-C, uses next-generation sequencing of methylation and fragmentation patterns in circulating DNA with machine learning to detect colorectal cancer and advanced adenomas. In a 1,000-patient study at Digestive Disease Week 2023 it showed 93 percent sensitivity for colorectal cancer and 54 percent for advanced adenomas at 92 percent specificity. A 15,000-patient, 100-site FDA registrational trial (NCT06059963) enrolled its first patient in January 2024, with Quest's Lewisville, Texas laboratory as the single testing site. UDX announced a Series B initial close of about $70 million in November 2023 including Quest, completed in August 2024 with new investor Olympus Innovation Ventures.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Madrid
- Type: diagnostics
- Website: https://www.universaldx.com/

## Notes

- US office moved from Cambridge, MA (2023-2024 releases) to Dallas, TX (current website). Series B extension amount not disclosed.

## Sources

- Official website: https://www.universaldx.com/
- Quest collaboration and Series B initial close (Nov 2023): https://cdn.prod.website-files.com/60925e59116a323839bdf90a/655b7ee215dc0e6a169bd932_2023_11_19%20UDX%20US%20Press%20release.pdf
- Series B close and FDA trial (Aug 2024): https://cdn.prod.website-files.com/60927bf52450bc2ed1129413/66bceb91587a66e050bd59a6_2024_08%20UDX%20PR%20release%20Series%20B%20Extension.pdf
- Press page: https://www.universaldx.com/press

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)

---
JSON: https://onco.cc/api/v1/entities/universal-dx.json